Litigation Finance Investing 2026: How Legal Funding Works as an Alternative Asset

Is litigation finance worth a slot in your portfolio?

Here is the honest take: litigation finance deserves a small satellite position for the right investor and a hard pass for everyone else. The appeal is real. Returns are driven by courtrooms, not by the Fed or earnings season. The drawbacks are just as real. Outcomes are all-or-nothing, cash can be locked up for years, and you usually cannot sell if you change your mind.

The mechanics are simple to state. A plaintiff or a law firm needs money to fund a case. Legal fees, expert witnesses and discovery can run into the millions for a complex commercial dispute. A funder puts up that capital, takes a contractual slice of any recovery, and absorbs the loss if the case fails. That non-recourse feature is the whole point, and the whole risk.

My view: if you hold a diversified 401(k) or brokerage account and you have a few percent you could genuinely afford to lock away for five to eight years, this asset class is worth understanding. If you are still building an emergency fund, skip it. No amount of “low correlation” marketing makes up for a bill you cannot pay.

One thing to get straight before going further. The question is not “will litigation funders make money on average?” Plenty do. The question is whether your access route, fees and position size leave you better off after the delays and the zeros. That is where retail investors usually get it wrong.

What are the main types of litigation funding?

Three buckets, and they behave very differently.

Type	Who gets the money	Typical ticket (rough)	Risk profile	Who can invest
Commercial single-case	Corporate plaintiffs, patent holders, law firms	Hundreds of thousands to tens of millions	One ruling decides the bet	Institutions, accredited investors, specialist funds
Portfolio funding	Law firms or companies with many claims	Millions to hundreds of millions	Spread across cases, but correlated through the same firm or legal theory	Institutions, listed funders
Consumer pre-settlement	Individual plaintiffs, often injury claims	Hundreds to tens of thousands of dollars	Many small advances, heavy regulation and reputational scrutiny	Niche private vehicles

Commercial single-case funding is the classic. A company with a strong patent claim cannot afford to litigate against a giant, so a funder pays the freight. If the case wins, the funder gets its capital back plus a return. If it loses, the money is gone. Each deal is a concentrated bet.

Portfolio funding bundles cases together, usually through a law firm. It sounds diversified, and it is, partly. But if every case in the book runs through one firm, in one court, on one legal theory, a single bad appellate ruling can hit them all at once. Ask what the correlation really looks like, not what the brochure says.

Consumer pre-settlement advances give a plaintiff living expenses while a case drags on. Costs to the consumer can be steep, and states handle it differently. I would not send a retail investor here. The returns come with reputational and regulatory baggage that most people do not want in their portfolio.

How do litigation finance investors actually make money?

The cash comes from one source: a judgment or a settlement. How the funder’s cut is calculated is a matter of contract.

A common shape is “greater of”: the funder receives the larger of a multiple of capital invested or a percentage of the recovery. As a rough range, multiples somewhere around 2x to 4x and percentages around 20% to 40% show up often, with step-ups that reward the funder when a case runs longer. Treat those as orientation, not a quote. A specific agreement can sit well outside them, and you should never underwrite a deal off a generic range.

Two ideas matter more than the headline multiple.

• Multiple of money is not the same as annualized return. A 3x over eight years is a very different outcome from 3x over two. In litigation, delay eats IRR quietly, because appeals and enforcement stretch timelines far past the initial estimate.
• The average hides the distribution. A healthy-looking book might have a large share of cases that return little or nothing, offset by a few big winners. If you only see the average, you do not understand your risk.

The best-known public player, Burford Capital, reports performance on its concluded cases and has historically disclosed strong returns on those, with wide dispersion between individual matters. I am deliberately not quoting a specific figure here, because the numbers move with each filing and depend on how they are calculated. Read the most recent annual report and investor presentation yourself, and pay special attention to how much of reported earnings is unrealized fair-value gain versus cash actually received.

Is litigation finance really uncorrelated with stocks and bonds?

Half true, and the half that is false is the half retail investors touch.

The true half first. A district judge deciding a patent case does not look at the S&P 500. Case outcomes are driven by evidence, law and strategy. In a year like 2022, when stocks and bonds fell together, an asset whose payoffs are tied to court calendars looked attractive to institutions hunting for diversifiers. That logic holds.

Now the false half. If you buy a listed funder, you are buying a stock. Its price reacts to interest rates, credit conditions, risk appetite and the news cycle around big cases. The underlying assets may be uncorrelated; the ticker is not. Add in the fact that earnings depend on fair-value estimates of unfinished cases, and quarterly results can swing hard on legal milestones rather than cash.

So if “low correlation” is your reason for buying, ask which layer you actually own. A private fund holding case interests is closer to the thesis. A public stock is a different animal.

What are the real risks, and what does a failure look like?

Most marketing skips this section. I won’t.

Risk	What happens	What to check
Binary outcome	A loss can mean a total write-off of that position	Number of cases, largest single exposure
Duration	Appeals and enforcement stretch timelines and crush IRR	Historical time to resolution on concluded cases
Illiquidity	Lockups, thin secondary market	Redemption terms, fund life
Collection	You win, then cannot collect	Defendant’s assets and where they sit
Control	Disputes over who decides whether to settle	Settlement-control language in the agreement
Valuation	Unrealized gains can overstate real performance	Fair-value methodology, auditor commentary
Regulation and tax	Disclosure rules, possible new taxes	State laws, court rules, pending federal bills

A cautionary example worth studying: the YPF case. Burford funded claims tied to the bankruptcy of Petersen, a company connected to Argentina’s YPF, and a New York federal court entered a very large judgment against Argentina, in the multi-billion-dollar range. On paper, a triumph. But the defendant is a sovereign nation. The judgment has been fought on appeal, and collecting from a sovereign is its own multi-year campaign with no guarantee. The status keeps changing, so verify current developments before forming a view. The lesson does not change: a judgment is not cash. If your valuation counts the verdict as money in the bank, you have taken on the collection risk without being paid for it.

Control fights are real too. Disputes between funders and clients over settlement decisions have landed in court, including a widely reported dispute involving a large food distributor and a funder. Whoever holds the pen on settlement can change your return, so that clause matters more than most people think.

For a sense of how mass-claim litigation unfolds over many years, with all the delays that implies for anyone with money tied to it, the Allergan BIOCELL breast implant lawsuit breakdown is a useful real-world illustration of timelines, claimants and defense strategy.

How can a regular investor or an accredited investor get access?

Your route depends on who you are.

Retail investors: public equities. The practical door is buying shares of a listed specialist. Burford Capital is the largest and most recognizable. Others trade on foreign exchanges, such as Omni Bridgeway in Australia and Litigation Capital Management on London’s AIM. You buy them like any other stock, and you take on all the usual equity volatility. You also owe tax on gains, so a refresher on how capital gains are taxed is worth a few minutes.

Accredited investors: private funds and platforms. Under SEC Regulation D, many private offerings are limited to accredited investors. The traditional test is roughly $200,000 in individual income (or $300,000 jointly) for the last two years, or more than $1 million in net worth excluding your primary home. Rules can be updated, so confirm against the SEC’s current definition. Some online platforms offer case-level investing. That puts the burden of selecting cases on you, which is exactly the skill that separates professionals from amateurs.

Institutions and family offices: direct deals and portfolios. Pension funds, endowments and insurers work with specialist managers (Parabellum, Longford, Bench Walk and Fortress’s legal assets group are among the better-known names) and negotiate bespoke terms. Individuals mostly cannot replicate this, though knowing that sophisticated money does diligence on these assets is mildly reassuring.

A short readiness checklist:

• I can lose this entire position without changing my lifestyle
• It is a single-digit percentage of my investable assets
• I have confirmed my accredited status and any state or residency limits
• I know the number of cases, the largest single case weight and the law-firm concentration
• I have read the concluded-case history, including the losses
• I have totaled every fee on one page

What do litigation finance funds charge?

Fees compound against you in a slow asset. A rough picture for private vehicles: a management fee in the neighborhood of 1.5% to 2% per year and a performance fee around 20%, with a hurdle in some funds, plus fund-level expenses. These are ballpark figures. Ask for the actual schedule.

Access route	Typical cost structure	Notes
Listed stock	Brokerage commissions (often zero), spread, taxes	Most transparent, most liquid, most volatile
Private fund	Management fee + carry + expenses	Often high minimums, multi-year lockup
Platform case deal	Platform fee + success share	Terms differ case by case

Here is the part people miss. The management fee keeps running whether or not a case resolves. If a three-year fund turns into a seven-year fund because of appeals, you pay the extra years. Model your net return under a delayed scenario, not the sales deck’s base case.

The tax side is still moving. Lawmakers in Washington have floated proposals to tax litigation funding proceeds at a punitive rate, and one such idea surfaced during the 2025 budget debate before being dropped from the final package. It could return in some form. Meanwhile, funds structured as partnerships can send complicated K-1s, so factor in accounting costs and timing. Talk to a CPA before you commit.

If total-cost thinking sounds familiar, it is the same discipline as pricing a purchase over its lifetime. Anyone who has worked through what an air conditioner really costs to run knows the sticker price is only the opening bid.

How is litigation finance regulated in the US?

There is no single federal rulebook. It is a patchwork.

• State law. Some states regulate consumer pre-settlement advances with fee caps, contract disclosures and registration. A growing number have also passed rules about disclosing third-party funding in litigation.
• Court rules. Certain federal judges require parties to disclose funders. Delaware’s federal bench has been prominent here, especially in patent cases.
• Congress. Proposals have targeted foreign funding, disclosure and taxation. Nothing has settled into a durable national framework.

My read: the direction of travel is transparency and taxation, not prohibition. The industry is simply too large and too embedded. But more disclosure can change negotiating dynamics, and any new tax would hit net returns directly. Treat regulation as a live variable, not a footnote.

For a sense of the type of mass litigation that attracts funder attention, see this breakdown of the opioid distributor and pharmacy litigation, which shows how multi-defendant claims develop across jurisdictions.

Who is litigation finance right for, and what is a sensible first step?

It suits a patient investor with surplus capital, an already-diversified core of stocks and bonds, and the temperament to see a position go to zero without panic. It does not suit someone who might need the cash within a few years, someone chasing double-digit headlines, or someone who has not read the fee and control terms.

If you are curious, here is the order I would go in. First, read the annual report of one listed funder from cover to cover and focus on the concluded-case table and the fair-value notes. Second, if you still like it, buy a small stock position and live with the price swings for a while. Third, only if you qualify as accredited and you understand the lockups, read a private fund’s subscription documents line by line before sending a dollar. Skip the step of jumping straight into single-case deals. That is how people end up learning the asymmetry the hard way.

One practical caution if you use an AI tool to summarize long agreements: verify every number against the source. Summaries invent figures, and a fabricated fee line costs real money.

Related reading

• Opioid distributor and pharmacy lawsuit explained
• Allergan BIOCELL breast implant lawsuit guide
• Capital gains tax guide 2026
• Air conditioner buying guide 2026

This article is informational and is not investment, legal or tax advice. Litigation finance and other alternative assets can result in the loss of your entire investment. Fees, return multiples, tax treatment and regulations change frequently, so confirm current terms and consult a qualified professional before investing.